Effectiveness of Pfizer-BioNTech mRNA Vaccination against COVID-19 Hospitalization among Persons Aged 12–18 Years — United States, June–September 2021
Morbidity and Mortality Weekly Report
What is already known about this topic? Persons aged 12–18 years are eligible to receive COVID-19 vaccine. Currently, data are lacking on real-world vaccine effectiveness against COVID-19 hospitalization in adolescents. What is added by this report? Among hospitalized U.S. patients aged 12–18 years, vaccine effectiveness of 2 doses of Pfizer-BioNTech vaccine against COVID-19 hospitalization during June–September 2021, was 93% (95% confidence interval = 83%–97%). What are the implications for public health practice? This evaluation demonstrated that 2 doses of Pfizer-BioNTech vaccine were highly effective in preventing COVID-19 hospitalization among persons aged 12–18 years. Findings reinforce the importance of vaccination to protect U.S. youths against severe COVID-19.
Olson, Samantha M.; Newhams, Margaret M.; Halasa, Natasha B.; Price, Ashley M.; Boom, Julie A.; Sahni, Leila C.; Irby, Katherine; Walker, Tracie C.; Schwartz, Stephanie P.; Pannaraj, Pia S.; Maddux, Aline B.; Bradford, Tamara T.; Nofziger, Ryan A.; Boutselis, Benjamin J.; Cullimore, Melissa L.; Mack, Elizabeth H.; Schuster, Jennifer E.; Gertz, Shira J.; Cvijanovich, Natalie Z.; and Kong, Michele, "Effectiveness of Pfizer-BioNTech mRNA Vaccination against COVID-19 Hospitalization among Persons Aged 12–18 Years — United States, June–September 2021" (2021). School of Medicine Faculty Publications. 284.